146 related articles for article (PubMed ID: 23107835)
1. 68Ga-DOTA-NOC PET and peptide receptor radionuclide therapy in management of bilateral ovarian metastases from gastrointestinal carcinoid.
Singla S; Gupta S; Reddy RM; Durgapal P; Bal CS
Jpn J Clin Oncol; 2012 Dec; 42(12):1202-6. PubMed ID: 23107835
[TBL] [Abstract][Full Text] [Related]
2. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid.
Ambrosini V; Castellucci P; Rubello D; Nanni C; Musto A; Allegri V; Montini GC; Mattioli S; Grassetto G; Al-Nahhas A; Franchi R; Fanti S
Nucl Med Commun; 2009 Apr; 30(4):281-6. PubMed ID: 19247211
[TBL] [Abstract][Full Text] [Related]
3. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours.
Oberg K; Eriksson B
Best Pract Res Clin Endocrinol Metab; 2005 Jun; 19(2):265-76. PubMed ID: 15763700
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine tumor imaging with 68Ga-DOTA-NOC: physiologic and benign variants.
Kagna O; Pirmisashvili N; Tshori S; Freedman N; Israel O; Krausz Y
AJR Am J Roentgenol; 2014 Dec; 203(6):1317-23. PubMed ID: 25415711
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
7. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data.
Hofmann M; Maecke H; Börner R; Weckesser E; Schöffski P; Oei L; Schumacher J; Henze M; Heppeler A; Meyer J; Knapp H
Eur J Nucl Med; 2001 Dec; 28(12):1751-7. PubMed ID: 11734911
[TBL] [Abstract][Full Text] [Related]
8. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.
Kwekkeboom DJ; de Herder WW; Kam BL; van Eijck CH; van Essen M; Kooij PP; Feelders RA; van Aken MO; Krenning EP
J Clin Oncol; 2008 May; 26(13):2124-30. PubMed ID: 18445841
[TBL] [Abstract][Full Text] [Related]
9. Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer.
Ocak M; Demirci E; Kabasakal L; Aygun A; Tutar RO; Araman A; Kanmaz B
Nucl Med Commun; 2013 Nov; 34(11):1084-9. PubMed ID: 23939265
[TBL] [Abstract][Full Text] [Related]
10. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
11. Changes in the expression of somatostatin receptor imaging following Y-90 lanreotide therapy for carcinoid tumor: a flare response?
Popadic S; Al-Nahhas A; Naili Q; Todd J; Meeran K
Clin Nucl Med; 2005 Apr; 30(4):238-40. PubMed ID: 15764878
[TBL] [Abstract][Full Text] [Related]
12. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE.
Velikyan I; Xu H; Nair M; Hall H
Nucl Med Biol; 2012 Jul; 39(5):628-39. PubMed ID: 22336375
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor expressing bilateral ovarian metastases detected by (68)Ga DOTANOC PET/CT.
Arora S; Soundararajan R; Joshi P; Kumar R; Bal C
Clin Nucl Med; 2015 Jun; 40(6):496-8. PubMed ID: 25546200
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
[TBL] [Abstract][Full Text] [Related]
15. Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1.
Swärd C; Bernhardt P; Johanson V; Schmitt A; Ahlman H; Stridsberg M; Forssell-Aronsson E; Nilsson O; Kölby L
Cancer Biother Radiopharm; 2008 Feb; 23(1):114-20. PubMed ID: 18298335
[TBL] [Abstract][Full Text] [Related]
16. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
Wild D; Schmitt JS; Ginj M; Mäcke HR; Bernard BF; Krenning E; De Jong M; Wenger S; Reubi JC
Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1338-47. PubMed ID: 12937948
[TBL] [Abstract][Full Text] [Related]
17. Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy.
Virgolini I; Patri P; Novotny C; Traub T; Leimer M; Füger B; Li SR; Angelberger P; Raderer M; Wogritsch S; Kurtaran A; Kletter K; Dudczak R
Ann Oncol; 2001; 12 Suppl 2():S41-5. PubMed ID: 11762351
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
19. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
Förster GJ; Engelbach MJ; Brockmann JJ; Reber HJ; Buchholz HG; Mäcke HR; Rösch FR; Herzog HR; Bartenstein PR
Eur J Nucl Med; 2001 Dec; 28(12):1743-50. PubMed ID: 11734910
[TBL] [Abstract][Full Text] [Related]
20. Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy.
Wiedenmann B; Bäder HM; Scherubl H; Fett U; Zimmer T; Hamm B; Koppenhagen K; Riecken EO
Semin Oncol; 1994 Oct; 21(5 Suppl 13):29-32. PubMed ID: 7992077
[No Abstract] [Full Text] [Related]
[Next] [New Search]
